Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Safety and efficacy of adjuvant subcutaneous trastuzumab in human epidermal growth factor receptor 2-positive early breast cancer: Final results of the SafeHER study

Published:2022-08 Issue: Volume:64 Page:151-158
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Gligorov Joseph^ORCID,Pivot Xavier,Ataseven Beyhan^ORCID,De Laurentiis Michelino,Jung Kyung Hae,Manikhas Alexey,Abdel Azim Hamdy,Gupta Kushagra,Alexandrou Ari^ORCID,Herraez-Baranda Luis,Tosti Nadia,Restuccia Eleonora

Funder

Novartis

Pfizer

Eisai

Roche

AstraZeneca

Gilead Sciences

Amgen

F. Hoffmann-La Roche

Eli Lilly and Company

Meso Scale Diagnostics

Genentech

Takeda Pharmaceutical Company

Publisher

Elsevier BV

Subject

General Medicine,Surgery

Reference19 articles.

1. The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine;Ross;Oncologist,2009

2. St. Gallen 2011: summary of the consensus discussion;Gnant;Breast Care,2011

3. Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;Aebi;Ann Oncol,2011

4. Recent advances and optimal management of human epidermal growth factor receptor-2-positive early-stage breast cancer;Batoo;J Carcinog,2019

5. A recombinant human enzyme for enhanced interstitial transport of therapeutics;Bookbinder;J Contr Release,2006

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Unveiling Neoadjuvant Therapy: Insights and Outlooks for HER2-Positive Early Breast Cancer;Current Treatment Options in Oncology;2024-08-17

2. Recent Developments in Convenience of Administration of the Anti-CD38 Antibody Isatuximab: Subcutaneous Delivery and Fast Intravenous Infusion in Patients With Multiple Myeloma;Clinical Lymphoma Myeloma and Leukemia;2024-06

3. Subcutaneous Trastuzumab: An Observational Study of Safety and Tolerability in Patients With Early HER2‐Positive Breast Cancer;International Journal of Breast Cancer;2024-01

4. Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients’ With HER2-Positive Metastatic Breast Cancer;Clinical Breast Cancer;2023-10

5. Six-Year Survival Outcomes for Patients with HER2-Positive Early Breast Cancer Treated with CT-P6 or Reference Trastuzumab: Observational Follow-Up Study of a Phase 3 Randomised Controlled Trial;BioDrugs;2023-03-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3